Stock Analysis
Immunovant, Inc. (IMVT) Stock Analysis
Immunovant, Inc. (IMVT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Immunovant, Inc. (IMVT) currently has an AIQ Score of 52/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Quality is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
IMVT at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $34.18 |
| AIQ Score | 52/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $7.06B |
| P/E Ratio (TTM) | -13.35 |
| Forward P/E | — |
| EPS (Q2 FY2027) | -$0.47 |
| Revenue (Q2 FY2027) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.58 |
| Volume | 864.88K |
| 52-week range | $21.86-$45.42 |
| RSI 14 | 58.06 |
| 50-Day SMA | $32.64 |
| 200-Day SMA | $32.35 |
| Analyst Price Target | — |
| Next Earnings | Feb 5, 2027 |
IMVTImmunovant, Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum61
- Value—
- Quality42
- Risk resilience52
- Sentiment—
IMVT Stock Analysis Summary
Immunovant, Inc. (IMVT) currently has an AIQ Score of 52/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Quality is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, IMVT has AIQ Score of 52/100 with Momentum base of 61/100 and fading Quality at 42/100. Wait for component alignment before adding exposure.
Healthcare · -2.48% stock move · IMVT classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is IMVT Bullish or Bearish Right Now?
IMVT currently has a neutral overall setup. Momentum is the strongest factor at 61/100, while Quality is weakest at 42/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Price is +4.73% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (33 vs 6).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
IMVT's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 7 neutral, and 6 sell votes. IMVT's 14-day RSI is 58.06, which places the stock in a constructive momentum range. IMVT's beta is 1.58, indicating greater market sensitivity than the broad market.
What Changed in IMVT?
The largest recent change in IMVT is Momentum moving up by 5.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the IMVT Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
IMVT Decision Framework
Public evidence layers, setup checks, and risk context for Immunovant, Inc..
Immunovant, Inc. (IMVT) Stock Analysis
Immunovant, Inc. has an AIQ Score of 52/100 in a Neutral regime. Momentum is strongest at 61/100. Beta is 1.58, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | IMVT is in a Neutral AIQ regime with score 52/100. |
| Signal Conflict | The primary conflict is that momentum leads at 61/100 while quality lags at 42/100. |
| Factor Evidence | Momentum 61/100 · Quality 42/100 · Risk 52/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 61/100.
Momentum is 61/100 and RSI (14) is 58.1.
IMVT is in a Neutral regime at 52/100.
Risk factor is 52/100 with beta 1.58 and annual volatility 58.62%.
Current conflict: momentum leads at 61/100 while quality lags at 42/100.
IMVT Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
IMVT Fundamentals
IMVT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
IMVT Technical Analysis
IMVT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
IMVT Stock Catalysts
Track IMVT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
IMVT Dividend Analysis
IMVT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
IMVT Financial Data
IMVT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
IMVT Risk Analysis
IMVT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
IMVT Stock News
IMVT stock news, market tone, recent headlines, and catalyst context.
IMVT vs Biotechnology Peers
Current peer cohort: IMVT · INBX · INSM · INVA · IRON. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| IMVT Current stock | 52/100 | — | 61/100 | 52/100 | 0.9 | 58.62% | Current |
| INBX Inhibrx Biosciences Inc. | 40/100 | — | 50/100 | 40/100 | 0.49 | 82.28% | IMVT vs INBX |
| INSM Insmed Incorporated | 57/100 | 55/100 | 61/100 | 49/100 | -0.48 | 63.12% | IMVT vs INSM |
| INVA Innoviva, Inc. | 67/100 | 92/100 | 43/100 | 74/100 | -0.64 | 25.21% | IMVT vs INVA |
| IRON Disc Medicine, Inc. | 65/100 | — | 75/100 | 51/100 | 0.1 | 63.55% | IMVT vs IRON |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for IMVT: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching IMVT
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for IMVT
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
IMVT Stock FAQ
What is IMVT stock price today?
Immunovant, Inc.'s current stock price is $34.18. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is IMVT bullish or bearish right now?
IMVT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is IMVT's market cap?
IMVT's market cap is $7.06B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is IMVT's current P/E ratio?
IMVT's current P/E ratio is -13.35 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is IMVT's RSI?
IMVT's 14-day RSI is 58.06 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is IMVT above its 50-day and 200-day moving averages?
IMVT is 4.73% from its 50-day SMA and 5.67% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is IMVT's next earnings date?
IMVT's next earnings date is currently listed as Feb 5, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does IMVT pay a dividend?
IMVT's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.